Therapeutic Asset Ratings
1,553 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
gc203 til
Tumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Early P1
C
(39)
Gdc-0449
Sarcoma
OHSU Knight Cancer Institute
Early P1
C
(39)
Gdt Cell Targeting B7-H3 Chimeric Antigen Receptor
Relapsed/Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early P1
C
(39)
Gentamycin
Spina Bifida
Medstar Health Research Institute
Early P1
C
(39)
Gentamycin
Urinary Tract Infection
Medstar Health Research Institute
Early P1
C
(39)
Glutamine
Traumatic Brain Injury
Assiut University
Early P1
C
(39)
Glycerol Phenylbutyrate
Developmental And Epileptic Encephalopathy
Weill Medical College of Cornell University
Early P1
C
(39)
Glycerol Phenylbutyrate
STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder
Weill Medical College of Cornell University
Early P1
C
(39)
Gly-Low
Depressive Disorder
Hoskinson Health and Wellness Clinic
Early P1
C
(39)
Gmcn-508B
Beta-Thalassemia Major
First Affiliated Hospital of Guangxi Medical University
Early P1
C
(39)
gt316
GT316
Grit Biotechnology
Early P1
C
(39)
gt801
B-Cell Acute Lymphoblastic Leukemia
Grit Biotechnology
Early P1
C
(39)
gt801
B-Cell Non-Hodgkin Lymphoma
Grit Biotechnology
Early P1
C
(39)
gt801
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Grit Biotechnology
Early P1
C
(39)
Hcr-188
Obesity Disorder
Helicore Biopharma, Inc.
Early P1
C
(39)
Hec-016
CAR T-Cell Therapy
Shenzhen Fifth People's Hospital
Early P1
C
(39)
Hengge Liejing
Type 2 Diabetes Mellitus
Fujian Medical University Union Hospital
Early P1
C
(39)
Hengge Liejing
Metabolic Dysfunction-Associated Steatotic Liver Disease
Fujian Medical University Union Hospital
Early P1
C
(39)
her2bbζ/cd19t+ t cells
Idiopathic Inflammatory Myopathy
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early P1
C
(39)
her2bbζ/cd19t+ t cells
Thrombocytopenia Due To Immune Destruction
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early P1
C
(39)
her2bbζ/cd19t+ t cells
Primary Biliary Cholangitis
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early P1
C
(39)
her2bbζ/cd19t+ t cells
Rheumatoid Arthritis
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early P1
C
(39)
her2bbζ/cd19t+ t cells
Sjogren Syndrome
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early P1
C
(39)
her2bbζ/cd19t+ t cells
Systemic Lupus Erythematosus
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early P1
C
(39)
her2bbζ/cd19t+ t cells
Systemic Sclerosis
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early P1
C
(39)
Showing 501 to 525 of 1,553 assets
Previous
Page 21 of 63
Next